Skip to main content
Archives of Disease in Childhood logoLink to Archives of Disease in Childhood
. 2005 Sep 27;91(1):47–51. doi: 10.1136/adc.2004.071241

Exercise capacity in apparently healthy survivors of cancer

E De Caro 1,2,3, F Fioredda 1,2,3, M G Calevo 1,2,3, A Smeraldi 1,2,3, M Saitta 1,2,3, G Hanau 1,2,3, M Faraci 1,2,3, F Grisolia 1,2,3, G Dini 1,2,3, G Pongiglione 1,2,3, R Haupt 1,2,3
PMCID: PMC2083103  PMID: 16188959

Abstract

Aims

To evaluate cardiopulmonary exercise tolerance in a large cohort of apparently healthy paediatric cancer survivors in order to determine their participation in sporting activities.

Methods

A total of 84 young (<21 years) asymptomatic childhood cancer survivors, who had been exposed to anthracyclines (mean dose 212 mg/m2) and/or chest irradiation (median dose 2000 cGy), with normal left ventricular systolic function at rest (fractional shortening >29%), and 79 healthy controls were studied. Exercise testing was performed on a treadmill ergometer. Gas exchange analysis and derived variables were measured on a breath‐by‐breath basis. Pulmonary functional evaluation was performed before exercise. Echocardiographic evaluation at rest was performed within one month before the exercise test.

Results

There were no differences in exercise responses between patients and controls. In boys <13 years, mean VO2 max was slightly but significantly lower than in controls. This finding was thought to be a result of decreased physical fitness as all the other exercise parameters were similar to those in the controls.

Conclusions

Results show that apparently healthy survivors of paediatric cancer can take part in dynamic sporting activities if they exhibit a normal response to cardiopulmonary exercise testing, while those that exhibit a reduced VO2 max should be re‐evaluated after an aerobic training programme, and should undergo tailored dynamic physical activity if the VO2 max does not normalise.

Keywords: anthracycline therapy, subclinical myocardial damage, cancer survivors, cardiac late effects, exercise test


Physical activity is important for a healthy lifestyle in children, particularly in survivors of cancer, who need to regain psychophysical wellbeing.1,2,3 However, exercise capacity can be reduced in these patients.4,5,6,7 Many have received chemotherapy with anthracycline containing regimens and/or chest irradiation and are thereby exposed to the attendant risk of pulmonary dysfunction and late onset cardiac toxicity.8,9 Although the risk is mainly related to the cumulative dosage received, no safe exposure limit exists, and the lack of symptoms and a normal cardiac systolic function at rest cannot guarantee the absence of any cardiac impairment.10,11,12 Exercise can unmask subclinical myocardial dysfunction, which may be adversely affected by an inappropriate physical activity.13,14 However, other factors, such as musculoskeletal dysfunction, lack of physical fitness, and psychological attitude can limit the exercise capacity of these patients, which, in many instances, can be positively affected by physical activity.15 A thorough functional evaluation is thus warranted to determine an appropriate level of physical activity for these patients. The aim of this study was to evaluate the cardiopulmonary exercise tolerance in a cohort of children and young adult survivors of paediatric cancer who had received cardiotoxic drugs, and were asymptomatic with normal systolic cardiac function at rest, in order to obtain information on their participation in sporting activities.

Methods

Subjects

Survivors of childhood cancer who had been treated at the Istituto Giannina Gaslini Children's Hospital in Genova between 1976 and 2000 and were assessed in the off‐therapy department between 2000 and 2002 were studied. Inclusion criteria were: to have received chemotherapy with anthracyclines and/or radiotherapy to the chest as part of the treatment, which had to be discontinued at least one year before assessment; to be in complete continuous remission; to be asymptomatic; and to have a normal echocardiographic evaluation at rest. A total of 178 patients fulfilled the study requirements. Subjects aged 7–21 years and who were physically able to perform the exercise capacity test were eligible for the study. The control group consisted of healthy, non‐athletic but physically active subjects with innocent murmurs who were examined for participation in sporting activities and had a normal echocardiographic examination at rest; they were comparable for sex and age.

For each eligible patient, information was collected on primary diagnosis, cumulative dose of anthracyclines received, and dose and field of chest irradiation. Since the anthracycline derivatives used have different cardiotoxic effects, the cumulative dose (mg/m2) was calculated as Adriamycin (ADR) equivalent.16 For cases and controls information was also collected on gender, age, weight and height at the time of the test, and body mass index (BMI) calculated as centiles.17 The test was performed after explanation of the exercise protocol to the subjects and their families; informed consent was obtained from all subjects.

Echocardiography

Echocardiographic evaluation at rest was performed within one month before the exercise test, utilising a Philips Sonos 5500 ultrasound system. Left ventricle dimensions were determined in the short axis of parasternal view and left ventricular systolic function was expressed as fractional shortening (FS), which was considered normal if ⩾29%.18

Exercise test

The exercise test protocol was performed in the morning, at least two hours after the last meal. To determine the relative physical fitness of each subject, information was collected on the patient's level of physical activity. Pulmonary functional evaluation, including spirometry and single breath carbon monoxide diffusing capacity, was performed before exercise. Exercise testing was then performed on a Galaxy MTC Climb 2000 treadmill ergometer, using a modified Bruce protocol. At the first stage the treadmill speed and slope were 1.7 mph and 0%, respectively, to allow the patients to warm up. At the second stage the treadmill slope was increased to 10%; thereafter slope and speed were increased according to the Bruce protocol.19 Blood pressure was measured utilising a mercury sphygmomanometer with an appropriately sized cuff at rest, at the end of each stage during exercise and until return to baseline into recovery. Heart rate and rhythm were monitored continuously throughout exercise and until return to baseline into recovery utilising a Cardiosoft Hellige Marquette 12 exercise electrocardiographic system. Oxygen consumption (VO2), carbon dioxide production, minute ventilation (VE), and derived variables were measured on a breath‐by‐breath basis utilising a Sensormedics Vmax 229 cardiopulmonary exercise testing system, which was calibrated before each test. Every patient was strongly encouraged to continue to the point of exhaustion; a respiratory exchange ratio (RER) ⩾1.1 was regarded as an indicator of maximal aerobic performance. The VO2 at the peak of the exercise was defined as maximal VO2 (VO2 max). The anaerobic threshold (AT) was determined using the ventilatory equivalent method or the V‐slope method, depending on which was better displayed on the diagram.

Statistical analysis

Data are presented as mean (SD) or median and range for continuous variables, and as absolute and relative frequencies for categorical variables. The ANOVA t test for continuous variables, and the χ2 or Fisher exact test for categorical variables were used to measure differences between cancer survivors and controls. A p value <0.05 was considered significant based on two‐tailed tests. The SPSS statistical software program was used for all analyses.

Results

Of 148 eligible patients, 84, all living within 200 km of our institution, agreed to participate; they formed the study group. For comparison, 79 healthy controls studied in the last three months were included in the study. The two groups were comparable for sex, age, and BMI (table 1).

Table 1 Characteristics of survivors and controls.

Survivors Controls
(n = 84) (n = 79)
Gender, n ((%)
 Male 58 (69) 53 (67)
 Female 26 (31) 26 (33)
Age group at test, mean (SD)
 7–13 y 10.2 (1.4) 10.1 (1.6)
 14–21 y 16.5 (2.2) 16.2 (2.5)
BMI >95th centile, n (%)
 Males, 7–13 y 11 (52) 9 (29)
 Males, 14–21 y 11 (30) 4 (18)
 Females, 7–13 y 2 (17) 3 (19)
 Females, 14–21 y 2 (14) 3 (30)

Over half of the male survivors <13 years of age at the exercise test had a BMI >95th centile compared to only 29% of the controls. The primary diagnosis of cancer survivors was acute lymphoblastic leukaemia (n = 34), Hodgkin's disease (n = 17), non‐Hodgkin's lymphoma (n = 9), acute non‐lymphoblastic leukaemia (n = 4), Ewing's sarcoma (n = 7), Wilms' tumour (n = 4), neuroblastoma (n = 3), rhabdomyosarcoma (n = 2), hepatoblastoma (n = 2), osteosarcoma (n = 1), and myelodysplasia (n = 1). Their mean age at diagnosis was 6.4 (4.1) years (range 25 days to 16.8 years), and their mean interval since the completion of anticancer treatment was 6.4 (3.4) years (range 1.0–15.3 years). Among those treated with anthracyclines, the mean cumulative dosage was 212 (100) mg/m2 (range 64–545 mg/m2); in those treated with chest radiotherapy, the median dose received was 2000 cGy (range 1000–4300 cGy, mean 1840 (775.6)). Table 2 shows the distribution of subjects according to potentially cardiotoxic treatments received and mean doses received of anthracyclines within each category.

Table 2 Distribution of survivors by cardiotoxic treatment.

ADR (mg/m2) equivalent Radiotherapy to the cardiac area (cGy) ADR equivalent mean cumulative dose (mg/m2)
None <3000 3000–5000 Total
None 1 1
<180 14 13 2 29 130 (28.7)
180–360 36 10 1 47 231 (49.4)
>360 2 5 7 458 (56.6)
Total 52 29 3 84 212 (100)

The echocardiographic parameters of survivors at rest were within normal range with a mean FS of 36.5% (±3.7). Pulmonary function at rest was normal in all except two survivors, who had a very mild restrictive pattern (86% and 88% respectively of the predicted total lung capacity). All survivors and controls were engaged in some physical activity, with younger children in either group mostly involved in leisure activities. Table 3 presents exercise results.

Table 3 Cardiopulmonary exercise testing parameters in cancer survivors and normal controls by age at test.

Total <13 y 13–21 y
Survivors (n = 84) Controls (n = 79) Survivors (n = 33) Controls (n = 47) Survivors (n = 51) Controls (n = 32)
VO2 max (ml/kg/m2) 36.5 (7.7) 38.2 (8.2) 34.0 (5.7) 38.9 (6.7)* 38.1 (8.4) 37.1 (10)
VO2 AT (ml/ Kg/m2) 24.4 (5.6) 24.4 (6.9) 23.6 (3.8) 24.6 (5.7) 24.9 (6.6) 24.2 (8.5)
VE (l/m2) 67.9 (23.3) 64.5 (21.8) 52.1 (12.5) 56.4 (19.0) 78.2 (23.0) 76.3 (20.4)
RER 1.1 (0.1) 1.1 (0.1) 1.1 (0.1) 1.1 (0.1) 1.1 (0.1) 1.1 (0.1)
O2 pulse (ml/beat) 10.1 (4.1) 9.6 (3.8) 6.8 (1.8) 7.6 (2.7) 12.3 (3.8) 12.4 (3.6)
Heart rate 192 (13) 189 (17) 193 (11) 189 (16) 191 (14) 189 (17)
Systolic BP (mm Hg) 147 (23) 148 (25) 132 (15) 134 (15) 157 (22) 168 (23)

VO2 max, oxygen consumption at peak exercise; VO2 AT, oxygen consumption at anaerobic threshold; VE, minute ventilation at peak exercise; RER, respiratory exchange ratio at peak exercise; BP, blood pressure at peak exercise.

*p<0.001.

All subjects exercised to the point of exhaustion. None developed cardiac symptoms or showed significant arrhythmias other than infrequent and isolated premature atrial or ventricular contractions, normally during the first stages of exercise or into recovery. There were no differences in exercise test results between patients and controls. Survivors <13 years of age had a mean value of VO2 max significantly lower than controls of the same age (34.0 (5.7) v 38.9 (6.7); p < 0.001). This difference was present only in male subjects (33.9 (6.0) v 40.8 (6.1); p < 0.0001), and disappeared among females (34.1 (5.5) v 35.3 (6.6); NS).

Only eight survivors (six males and two females), had VO2 max values <5th centile of the controls. Their cumulative dose of anthracyclines was 189–330 mg/m2, and only one patient had received chest radiotherapy at a cumulative dose of 2000 cGy in association with 210 mg of anthracyclines. In all the BMI was >95th centile for sex and age.

Discussion

Regular participation in physical activity is one of the strategies recently recommended by the American Heart Association for promoting cardiovascular health in childhood. Activities that generate energy expenditure ⩾50–60% of maximal exertion should be encouraged, and children with physical limitations should be included in activities specifically tailored to their physical ability.1 Survivors of paediatric cancer need to recover complete psychophysical growth, and therefore should be directed towards physical activity. However, late cardiotoxicity is a very important issue in such patients.

Differences exist among individuals in their sensitivity to the anthracycline damage, and even if cardiac changes are more likely to be observed after a cumulative dose >350–400 mg/m2, no safe dose exists since cardiac toxicity can be present with doses <180 mg/m2.20,21,22 Moreover, subclinical cardiac damage can be present despite the lack of symptoms and with a normal cardiac function at rest, and it is conceivable that regular physical activity of moderate or high intensity can negatively affect the natural history of the cardiac damage. Recommendations regarding participation in sporting activities are therefore very difficult in apparently healthy childhood cancer survivors who have received low dose anticancer treatment, as that an unproven restriction of their physical activity may be perceived by these patients as a decrease in their quality of life.23,24

Subclinical myocardial dysfunction can be unmasked under stress. Abnormalities of ventricular function, not detected or less pronounced at rest, have been shown in anthracycline treated patients by both exercise echocardiography and dobutamine stress echocardiography, in terms of a reduced increase of the fractional shortening and of a reduced end systolic left ventricular posterior wall dimension and percentage thickening, respectively.25,26,27,28,29,30 The usefulness of these techniques is limited to the evaluation of cardiac function and their clinical significance has yet to be ascertained. The role of the exercise test is still controversial because of the poor correlation of ventricular function with exercise capacity. Patients with heart failure can have a normal or near normal exercise capacity depending on several factors producing positive changes at the muscular, vascular, and neurohormonal level.31,32 Thus, even if there is limited data available from patients with anthracycline associated cardiomyopathy, exercise performance may be an unreliable surrogate for cardiac function in this population.33 However, cardiopulmonary exercise testing (CPET) addresses the body's global physiological adaptation to exercise, and it can therefore unmask compensatory mechanisms for the abnormal cardiac function.34 VO2 max is the best available index of functional exercise capacity, and even though in early mild cardiovascular disease the peak VO2 may still be normal, other specific physiological variables, such as AT and O2 pulse may become abnormal.34,35 Hauser et al performed exercise echocardiography and spiroergometry on 38 patients, and found a good correlation between cardiac function and exercise performance. In their study, exercise capacity, as measured by VO2 max, was similar to that of controls in the 28 patients that had a normal stress echo, but was significantly lower in the 10 patients who had decreased FS and ejection fraction after exercise.36

However, exercise capacity can be reduced in a large percentage of these patients by several factors other than cardiac toxicity, such as respiratory or musculoskeletal dysfunction, psychological attitude, lack of physical fitness, endocrine deficiencies, chronic fatigue, or peripheral neuropathies. Most of these not only do not contraindicate but can even be positively affected by a regular physical activity, even of moderate intensity.2,3,37,38,39,40,41,42 Moreover, early mild heart disease can be difficult to distinguish from lack of fitness, and response to an aerobic training regimen may help to distinguish between these two clinical entities.43,44 Finally, patients with heart failure can improve their exercise capacity with a tailored exercise training programme.32 In case of exercise intolerance, integrative CPET has the capability to address many questions about the limiting mechanism(s), and provides information not only of the patient's anaerobic threshold, but also of the level of exercise that the patient can perform without undue stress. Thus, the test results can guide the physician in both diagnosis and exercise prescription; we therefore believe that CPET may be the most useful initial test for the functional evaluation of these patients.

In our study, which is to our knowledge one of the largest in which CPET was carried out in paediatric cancer survivors, none in the group of older patients showed an abnormal exercise response, possibly because of an insufficient length of follow up. It is known that the incidence of cardiac abnormalities increases with time, and more than half of the patients exposed to anthracyclines will show cardiac abnormalities at 10–20 years from diagnosis; in this subgroup of our patients the mean interval since diagnosis was only 7.7 (3.4) years.22,45,46 Another possible explanation could be the low mean cumulative dose of anthracyclines that the patients had received, although any dose of anthracyclines can be cardiotoxic. Johnson et al assessed the long term impact of paediatric low dose anthracycline therapy on the circulatory response to moderate exercise, and found that the VO2 max was significantly lower in patients than in control subjects despite normal resting systolic function.6 Finally, an additional explanation might be that since most of these patients participated in regular sporting activities, they could be quite fit. However, whatever the cause, the normality of VO2 max and all other variables provides reassurance that no significant functional abnormality exists in these patients.43 Therefore, in our opinion these patients should be directed towards physical dynamic activity with no particular limitations. It is important to point out that in our patients we investigated the physical response to dynamic exercise, which primarily causes a volume load on the cardiovascular system, but the response to static exercise, which primarily causes a pressure load on the cardiovascular system, could be quite different.

What is already known on this topic

  • Exercise capacity can be reduced, even in apparently healthy survivors of paediatric cancer by several causes

  • Such patients are commonly restricted in their physical activities

What this study adds

  • The cardiopulmonary exercise test is useful for the functional evaluation of these patients

  • Recommendations regarding the level of participation in physical activities are given, based on the results of the cardiopulmonary exercise test

In the subgroup <13 years of age, male patients showed a mean VO2 max slightly but significantly lower than controls. In this subgroup of younger patients, in which the median interval between completion of therapy and test execution was 5.13 years, the mean BMI value was higher than in controls, although this difference did not reach statistical significance. In males the BMI was >95th centile in 11/21 cases; among these were all six patients that performed with VO2 max values <5th centile observed among controls. In females, BMI was >95th centile in 2/12 patients. The majority of our patients were acute lymphoblastic leukaemia survivors. These patients tend to experience increases in weight, relative weight, and body fat mass, especially in the first years after cessation of therapy.2,41,47 One of the several contributing factors to this is a decreased physical activity, that in some cases depends on a psychological attitude.3 Therefore, considering that all the other exercise parameters were not significantly different from those of controls, the reduction of the aerobic capacity observed in our patients, at least when overweight, was likely to be due to poor physical fitness. Surprisingly, the difference was noted only in males, possibly because of the higher activity level in boys than in girls.39 However, we believe that a new CPET performed after an aerobic conditioning programme is highly recommended in such patients, which could be directed towards an unrestricted aerobic activity in case of normal VO2 max, or an activity tailored below their anaerobic threshold. Obviously long term follow up of these patients is warranted.

Footnotes

Competing interests: none declared

References

  • 1.Williams C L, Hayman L L, Daniels S R.et al Cardiovascular health in childhood: a statement for health professionals from the Committee on Atherosclerosis, Hypertension, and Obesity in the Young (AHOY) of the Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 2002106143–160. [DOI] [PubMed] [Google Scholar]
  • 2.Talvensaari K K, Knip M, Lanning P.et al Clinical characteristics and factors affecting growth in long‐term survivors of cancer. Med Pediatr Oncol 199626166–172. [DOI] [PubMed] [Google Scholar]
  • 3.Calzolari A, Baronci C, Biondi G.et al Evaluation of a group of leukaemic children “off‐therapy”, towards their inclusion in physical activities. Int J Sports Cardiol 19852108–115. [Google Scholar]
  • 4.Pihkala J, Happonen J M, Virtanen K.et al Cardiopulmonary evaluation of exercise tolerance after chest irradiation and anticancer chemotherapy in children and adolescents. Pediatrics 199595722–726. [PubMed] [Google Scholar]
  • 5.Larsen R, Barber G, Heise C T.et al Exercise assessment of cardiac function in children and young adults before and after bone marrow transplantation. Pediatrics 199289722–729. [PubMed] [Google Scholar]
  • 6.Johnson D, Perrault H, Fournier A.et al Cardiovascular responses to dynamic submaximal exercise in children previously treated with anthracycline. Am Heart J 1997133169–173. [DOI] [PubMed] [Google Scholar]
  • 7.Sato T, Harada K, Tamura M.et al Cardiorespiratory exercise capacity and its relation to a new Doppler index in children previously treated with anthracycline. J Am Soc Echocardiogr 200114256–263. [DOI] [PubMed] [Google Scholar]
  • 8.Bleyer W A. The impact of childhood cancer on the United States and the world. CA Cancer J Clin 199040355–367. [DOI] [PubMed] [Google Scholar]
  • 9.Jenney M M, Faragher B, Morris Jones P H.et al Lung function and exercise capacity in survivors of childhood leukaemia. Med Pediatr Oncol 199524222–230. [DOI] [PubMed] [Google Scholar]
  • 10.Shan K, Lincoff A M, Young J B. Anthracycline induced cardiotoxicity. Ann Intern Med 199612547–58. [DOI] [PubMed] [Google Scholar]
  • 11.Praga C, Beretta G, Vigo P L.et al Adriamycin cardiotoxicity a survey of 1273 patients. Cancer Treat Rep 197863827–834. [PubMed] [Google Scholar]
  • 12.Ewer M S, Ali M K, McKay B. A comparison of cardiac biopsy grades and ejection fraction in patients receiving doxorubicin. J Clin Oncol 19842112–117. [DOI] [PubMed] [Google Scholar]
  • 13.Lang D, Hilger F, Binswanger J.et al Late effects of anthracycline therapy in childhood in relation to the function of the heart at rest and under physical stress. Eur J Pediatr 19955340–345. [DOI] [PubMed] [Google Scholar]
  • 14.Yeung S T, Yoong C, Spink J.et al Functional myocardial impairment in children treated with anthracyclines for cancer. Lancet 19916816–818. [DOI] [PubMed] [Google Scholar]
  • 15.Washington R L. Cardiopulmonary sequelae after bone marrow transplantation. J Pediatr 2000136280–282. [DOI] [PubMed] [Google Scholar]
  • 16.Perry M C.The chemotherapy source book, 3rd edn. Lippincott Williams and Wilkins 2001462
  • 17.Cole T J, Freeman J V, Preece M A. Body mass index references curves for the UK, 1990. Arch Dis Child 19957325–29. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Kremer L C M, van der Pal H J H, Offringa M.et al Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children; a systematic review. Ann Oncol 200213819–829. [DOI] [PubMed] [Google Scholar]
  • 19.Cumming G R, Everatt D, Hastman L. Bruce treadmill test in children; normal values in a clinic population. Am J Cardiol 19784169–75. [DOI] [PubMed] [Google Scholar]
  • 20.Steinherz I J, Steinherz P G, Tan C.et al Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 19912661672–1677. [PubMed] [Google Scholar]
  • 21.Lipshultz S E, Colan S D, Gelber R D.et al Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 1991324808–815. [DOI] [PubMed] [Google Scholar]
  • 22.Ali M K, Ewer M S, Gibbs H R.et al Late doxorubicin‐associated cardiotoxicity in children. Cancer 199474182–188. [DOI] [PubMed] [Google Scholar]
  • 23.Lipshultz S E, Sallan S E. Cardiovascular abnormalities in long‐term survivors of childhood malignancy. J Clin Oncol 1993111199–1203. [DOI] [PubMed] [Google Scholar]
  • 24.Eames G M, Crosson J, Steinberger J.et al Cardiovascular function in children following bone marrow transplantation: a cross‐sectional study. Bone Marrow Transplantation 19971961–66. [DOI] [PubMed] [Google Scholar]
  • 25.Weesner K M, Bledsoe M, Chauvenet A.et al Exercise echocardiography in the detection of anthracycline cardiotoxicity. Cancer 199168435–438. [DOI] [PubMed] [Google Scholar]
  • 26.De Wolf D, Suys B, Matthys D.et al Stress echocardiography in the evaluation of late toxicity after moderate dose of anthracycline therapy in childhood. Int J Pediatr Hematol Oncol 19941399–404. [Google Scholar]
  • 27.Smibert E, Carlin J B, Vidmar S.et al Exercise echocardiography reflects cumulative anthracycline exposure during childhood. Pediatr Blood Cancer 200442556–562. [DOI] [PubMed] [Google Scholar]
  • 28.Klewer S E, Goldberg S J, Donnerstein R L.et al Dobutamine stress echocardiography: a sensitive indicator of diminished myocardial function in symptomatic doxorubicin‐treated long‐term survivors of childhood cancer. J Am Coll Cardiol 199219394–401. [DOI] [PubMed] [Google Scholar]
  • 29.De Wolf D, Suys B, Verhaaren H.et al Low‐dose dobutamine stress echocardiography in children and young adults. Am J Cardiol 199881895–901. [DOI] [PubMed] [Google Scholar]
  • 30.Cottin Y, L'Hulilier I, Casasnovas O.et al Dobutamine stress echocardiography identifies anthracycline cardiotoxicity. Eur J Echocardiography 20001180–183. [DOI] [PubMed] [Google Scholar]
  • 31.Harrington D, Anker S D, Coats J S. Preservation of exercise capacity and lack of peripheral changes in asymptomatic patients with severe impaired left ventricular function. Eur Heart J 200122392–399. [DOI] [PubMed] [Google Scholar]
  • 32.Fang Z Y, Marwick T H. Mechanisms of exercise training in patients with heart failure. Am Heart J 2003145904–911. [DOI] [PubMed] [Google Scholar]
  • 33.Lipshultz S E, Colan S D. Cardiovascular trials in long‐term survivors of childhood cancer. J Clin Oncol 200422769–773. [DOI] [PubMed] [Google Scholar]
  • 34.Wassermann K, Hansen J E, Sue D Y.et al Chapter 7. Principles of exercise testing and interpretation, 3rd edn. Lippincott Williams and Wilkins 1999
  • 35.Weisman I M, Zeballos R J. An integrated approach to the interpretation of cardiopulmonary exercise testing. Clinics in Chest Medicine 199415421–445. [PubMed] [Google Scholar]
  • 36.Hauser M, Gibson B S, Wilson N. Diagnosis of anthracycline‐induced late cardiomyopathy by exercise‐spiroergometry and stress‐echocardiography. Eur J Pediatr 2001160607–610. [DOI] [PubMed] [Google Scholar]
  • 37.Jenney M M, Faragher B, Morris Jones P H.et al Lung function and exercise capacity in survivors of childhood leukaemia. Med Pediatr Oncol 199524222–230. [DOI] [PubMed] [Google Scholar]
  • 38.Hovi L, Er P, Rautonen J.et al Impaired muscle strength in female adolescents and young adults surviving leukemia in childhood. Cancer 199272276–281. [DOI] [PubMed] [Google Scholar]
  • 39.Matthys D, Verhaaren H, Benoit Y.et al Gender difference in aerobic capacity in adolescents after cure from malignant disease in childhood. Acta Paediatr 199382459–462. [DOI] [PubMed] [Google Scholar]
  • 40.Black P, Gutjahr P, Stopfkuchen H. Physical performance in long‐term survivors of acute leukaemia in childhood. Eur J Pediatr 1998157464–467. [DOI] [PubMed] [Google Scholar]
  • 41.Zee P, Chen C H. Prevalence of obesity in children after therapy for acute lymphoblastic leukemia. Am J Pediatr Hematol Oncol 19868294–299. [DOI] [PubMed] [Google Scholar]
  • 42.Ettinger R S, Heiney S P. Cancer in adolescents and young adults. Psychosocial concerns, coping strategies, and interactions. Cancer 1993713276–3280. [DOI] [PubMed] [Google Scholar]
  • 43.Weisman I M, Zeballos R J. Cardiopulmonary exercise testing. Pulmonary and Critical Care Update PCCU 1995112 [Google Scholar]
  • 44.Sharkey A M, Carely A B, Heise C T.et al Cardiac rehabilitation after cancer in children and young adults. Am J Cardiol 1993711488–1490. [DOI] [PubMed] [Google Scholar]
  • 45.Silber J H, Jakacki R, Larsen P L.et al Increased risk of cardiac dysfunction after anthracyclines in girls. Med Pediatr Oncol 199321477–479. [DOI] [PubMed] [Google Scholar]
  • 46.Steinherz L J. Anthracycline‐induced cardiotoxicity. Ann Intern Med 1997126827–828. [DOI] [PubMed] [Google Scholar]
  • 47.Turner‐Gomes S O, Lands L C, Halton J.et al Cardiorespiratory status after treatment for acute lymphoblastic leukemia. Med Pediatr Oncol 199626160–165. [DOI] [PubMed] [Google Scholar]

Articles from Archives of Disease in Childhood are provided here courtesy of BMJ Publishing Group

RESOURCES